Published in Thorax on August 01, 1977
Effect of oral salbutamol and slow-release aminophylline on exercise tolerance in chronic bronchitis. Thorax (1981) 2.06
Twice daily slow-release theophylline vs placebo for 'morning-dipping' in asthma. Br J Clin Pharmacol (1984) 1.48
The effect of posture on the sympathoadrenal response to theophylline infusion. Br J Clin Pharmacol (1983) 1.08
Potentiation of isoprenaline-induced plasma cyclic AMP response by aminophylline in normal and asthmatic subjects. Br J Clin Pharmacol (1978) 1.02
Intravenous salbutamol and aminophylline in asthma: a search for synergy. Thorax (1981) 0.93
The metabolic actions of intravenous salbutamol and aminophylline singly and in combination. Br J Clin Pharmacol (1981) 0.87
Recent advances in respiratory medicine. Postgrad Med J (1983) 0.82
Comparison between the effects of inhaled isoprenaline and fenoterol on plasma cyclic AMP and heart rate in normal subjects. Br J Clin Pharmacol (1984) 0.81
Saving asthmatics. Br Med J (1979) 0.75
A protein binding assay for adenosine 3':5'-cyclic monophosphate. Proc Natl Acad Sci U S A (1970) 23.79
Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem (1962) 12.79
Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science (1968) 4.38
Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise. Circ Res (1966) 3.95
A reduction in maximum mid-expiratory flow rate. A spirographic manifestation of small airway disease. Am J Med (1972) 2.82
The response to bronchodilators in intrinsic asthma. Q J Med (1961) 2.41
Synergism and potentiation with special reference to the combination of structural analogues. Pharmacol Rev (1956) 2.15
The potentiation of cardiac inotropic responses to norepinephrine by theophylline. J Pharmacol Exp Ther (1963) 1.81
Effects of atropine on heart rate and oxygen intake in working man. J Appl Physiol (1953) 1.66
Effects of catecholamines and adrenergic-blocking agents on plasma and urinary cyclic nucleotides in man. J Clin Invest (1972) 1.52
Cyclic adenosine 3',5'-monophosphate in human lung. Biochim Biophys Acta (1971) 1.44
Trial of combination of guanethidine and oxprenolol in hypertension. Br Med J (1976) 1.44
Effect of intravenous prednisolone in asthmatics with diminished adrenergic responsiveness. Lancet (1975) 1.36
Extracellular cyclic nucleotides. Ann N Y Acad Sci (1971) 1.01
Sources of cyclic nucleotides in plasma. J Clin Invest (1974) 0.97
Cyclic adenosine 3',5'-monophosphate concentration in plasma, adipose tissue and skeletal muscle in normal subjects and in patients with hyper- and hypothyroidism. J Clin Endocrinol Metab (1974) 0.87
Letter: Alpha-adrenoceptor-blocking drugs in asthma. Br Med J (1974) 0.82
Sympathomimetic xanthine broncholysis in obstructive ventilatory disorders. Int J Clin Pharmacol (1974) 0.82
Human and animal studies on the interactions between glyphylline and isoprenaline. J Asthma Res (1972) 0.82
Letter: Alpha-receptor-blocking drugs in bronchial asthma. Lancet (1975) 0.81
Twelve-minute walking test for assessing disability in chronic bronchitis. Br Med J (1976) 14.74
Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med (1992) 11.90
Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. Br Med J (1978) 4.93
Physical rehabilitation for the chronic bronchitic: results of a controlled trial of exercises in the home. Thorax (1977) 4.07
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis (1990) 3.70
Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet (2000) 3.68
The IgE-mediated release of an eosinophil leukocyte chemotactic factor from human lung. J Immunol (1971) 3.51
Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. Am Rev Respir Dis (1988) 3.45
Studies on eosinophil leucocyte migration. II. Factors specifically chemotactic for eosinophils and neutrophils generated from guinea-pig serum by antigen-antibody complexes. Clin Exp Immunol (1970) 3.09
Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis (1989) 3.06
Short term variability in FEV1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. Thorax (1987) 2.99
Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest (1986) 2.90
Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol (1991) 2.88
Audit of a tuberculosis contact tracing clinic. BMJ (1992) 2.80
Effect of attitudes and beliefs on exercise tolerance in chronic bronchitis. Br Med J (Clin Res Ed) (1983) 2.78
An eosinophil leukocyte chemotactic factor of anaphylaxis. J Exp Med (1971) 2.65
Detecting and reducing hospital adverse events: outcomes of the Wimmera clinical risk management program. Med J Aust (2001) 2.61
British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax (1996) 2.58
Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science (1990) 2.49
Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. JAMA (2001) 2.38
Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet (2002) 2.38
What is the optimum duration of anticoagulation for the management of patients with idiopathic deep venous thrombosis and pulmonary embolism? J R Coll Physicians Edinb (2010) 2.36
Lymph node tuberculosis: a comparison of various methods of treatment. Tubercle (1977) 2.35
Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ (1991) 2.32
T cells and eosinophils in the pathogenesis of asthma. Immunol Today (1992) 2.30
Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol (1997) 2.28
The effect of aerosol ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis. Thorax (1978) 2.19
CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status. Am Rev Respir Dis (1990) 2.18
Eosinophils, bronchial hyperreactivity and late-phase asthmatic reactions. Clin Allergy (1985) 2.15
Short term variability in FEV1: relation to pretest activity, level of FEV1, and smoking habits. Thorax (1984) 2.14
Studies on eosinophil leucocyte migration. I. Eosinophil and neutrophil accumulation following antigen-antibody reactions in guinea-pig skin. Clin Exp Immunol (1970) 2.13
Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol (1993) 2.11
Effect of oral salbutamol and slow-release aminophylline on exercise tolerance in chronic bronchitis. Thorax (1981) 2.06
Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet (1992) 2.06
The estimation of carbon dioxide pressure of mixed venous blood during exercise. Clin Sci (1967) 2.06
Leucoattractants enhance complement receptors on human phagocytic cells. Clin Exp Immunol (1979) 2.04
The relationship between infiltrating CD4+ lymphocytes, activated eosinophils, and the magnitude of the allergen-induced late phase cutaneous reaction in man. J Immunol (1988) 2.00
IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med (1996) 1.93
Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancement by IL-1 beta and tumour necrosis factor-alpha. Immunology (1992) 1.93
IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. Immunology (1990) 1.85
Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products. Clin Exp Immunol (1982) 1.84
Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis (1991) 1.84
Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med (1995) 1.83
Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) (1984) 1.83
T lymphocyte activation in acute severe asthma. Lancet (1988) 1.81
Survey of pulmonary tuberculosis in south and west Wales (1976-8). Br Med J (Clin Res Ed) (1982) 1.78
Anticoagulants in venous thromboembolism. BMJ (1988) 1.77
Identification and partial characterization of an exercise-induced neutrophil chemotactic factor in bronchial asthma. J Clin Invest (1982) 1.77
A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. Anesth Analg (1998) 1.76
Corticosteroid resistance in chronic asthma. Br Med J (Clin Res Ed) (1981) 1.75
The identification of fibrinopeptide B as a chemotactic agent derived from human fibrinogen. Br J Haematol (1974) 1.70
Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol (1997) 1.69
Eosinophils 1992. Immunol Today (1992) 1.69
Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am Rev Respir Dis (1992) 1.68
Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. Thorax (2001) 1.67
Human eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is alpha 4 beta 1 (very late antigen-4) dependent. J Immunol (1991) 1.67
The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today (1999) 1.67
Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol (1993) 1.67
Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest (1993) 1.66
Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med (1996) 1.64
Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J Exp Med (1991) 1.64
Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol (1989) 1.63
Membrane receptors for IgG and complement (C4, C3b and C3d) on human eosinophils and neutrophils and their relation to eosinophilia. J Immunol (1977) 1.63
Ludwig's angina. Report of a case and review of the literature. Arch Intern Med (1988) 1.62
Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis (1997) 1.60
Oxygen as a driving gas for nebulisers: safe or dangerous? Br Med J (Clin Res Ed) (1984) 1.60
Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol (1997) 1.59
Preferential messenger RNA expression of Th1-type cells (IFN-gamma+, IL-2+) in classical delayed-type (tuberculin) hypersensitivity reactions in human skin. J Immunol (1992) 1.59
Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood (1992) 1.59
Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4. Br J Pharmacol (1983) 1.56
The accumulation of 111In-eosinophils induced by inflammatory mediators, in vivo. Immunology (1991) 1.55
Killing of schistosomula of Schistosoma mansoni coated with antibody and/or complement by human leukocytes in vitro: requirement for complement in preferential killing by eosinophils. J Immunol (1979) 1.53
Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin Exp Allergy (1999) 1.53
Management of spontaneous pneumothorax-a Welsh survey. Postgrad Med J (2000) 1.53
Neutrophil chemotactic activity in antigen-induced late asthmatic reactions. N Engl J Med (1982) 1.51
Activated human eosinophils generate SRS-A leukotrienes following IgG-dependent stimulation. Nature (1985) 1.51
Pulmonary infection with mycobacterium xenopi: review of treatment and response. Thorax (1984) 1.50
Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med (1996) 1.50
The relationship between the differences in pressure and content of carbon dioxide in arterial and venous blood. Clin Sci (1967) 1.48
Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med (1999) 1.48
Twice daily slow-release theophylline vs placebo for 'morning-dipping' in asthma. Br J Clin Pharmacol (1984) 1.48
Mediators of immediate-type hypersensitivity in sputum from patients with chronic bronchitis and asthma. Lancet (1977) 1.45
The ECF-A tetrapeptides and histamine selectively enhance human eosinophil complement receptors. Nature (1977) 1.43
CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy. Am Rev Respir Dis (1993) 1.43
Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol (1995) 1.42
Phenotype of cells expressing mRNA for TH2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol (1995) 1.42
Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. Thorax (1993) 1.41
T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis (1992) 1.41
Lymph node tuberculosis: a comparison of treatments 18 months after completion of chemotherapy. Tubercle (1979) 1.40
"Opportunist" mycobacterial infections. Thorax (2000) 1.39
Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med (1997) 1.39
Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity. J Immunol (1991) 1.38
Postoperative pain after laparoscopic sterilisation. Anaesthesia (1989) 1.38
Hyposensitisation for food-induced hyperkinetic syndrome. Lancet (1993) 1.38